Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Other(1)

Detailed Status

Completed3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

completed375%
unknown125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_1

A Clinical Study to Evaluate the Safety and Efficacy of JHM03 in Adult Patients With Upper Limb Spasticity

NCT06584240
unknownphase_1

A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects

NCT03726866
completedphase_1

Pharmacokinetic Drug Interaction Between Revaprazan and Itopride HCl in Healthy Male Subjects

NCT01332890
completedphase_1

Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg)

NCT01353404

Clinical Trials (4)

Showing 4 of 4 trials
NCT06584240Phase 1

A Clinical Study to Evaluate the Safety and Efficacy of JHM03 in Adult Patients With Upper Limb Spasticity

Completed
NCT03726866Phase 1

A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects

Unknown
NCT01332890Phase 1

Pharmacokinetic Drug Interaction Between Revaprazan and Itopride HCl in Healthy Male Subjects

Completed
NCT01353404Phase 1

Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg)

Completed

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4